Coherus Biosciences | CHRS - Capitaux Propres Et Réserves





Capitaux Propres Et Réserves Changement Date
AbbVie USD -3.27B 628M 2025-12
Acadia Pharmaceuticals USD 917.27M 94.89M 2025-09
Akebia Therapeutics USD 32.61M 8.98M 2025-12
ALKERMES USD 1.75B 67.76M 2026-03
Alnylam Pharmaceuticals USD 1.08B 286.2M 2026-03
Amarin USD 449.41M 9.87M 2026-03
Amgen USD 9.19B 532M 2026-03
Baxter International USD 6.04B 86M 2026-03
Biogen USD 18.65B 394.9M 2026-03
BioMarin Pharmaceutical USD 6.21B 125.11M 2026-03
Bristol-Myers Squibb USD 20.07B 1.6B 2026-03
Coherus Biosciences USD 61.01M 26.76M 2025-12
Eli Lilly USD 31.2B 4.66B 2026-03
Fujifilm JPY 3.72T 230.16B 2025-12
Gilead Sciences USD 22.62B 1.16B 2025-12
Ironwood Pharmaceuticals USD -264.16M 44M 2025-09
Merck USD 45.88B 6.73B 2026-03
Myriad Genetics USD 337.4M 30.6M 2026-03
Pacira USD 653.89M 39.22M 2026-03
Perrigo USD 2.94B 1.51B 2025-12
Pfizer USD 90.1B 3.63B 2026-03
PTC Therapeutics USD -205.31M 49.56M 2025-12
Regeneron Pharmaceuticals USD 31.42B 166.7M 2026-03
Sarepta Therapeutics USD 1.14B 179.5M 2025-12
Teva Pharmaceutical Industries USD 8.23B 314M 2026-03
Vertex Pharmaceuticals USD 19.36B 696.1M 2026-03
Xencor USD 635.59M 10.27M 2025-12
Zoetis USD 3.33B 2.07B 2025-12